Tiziana Life Sciences received feedback based on the U.S. Food and Drug Administration Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS. Tiziana plans to accept the FDA’s recommendations and intends to start a Phase 2 study in the third quarter of 2023 as previously announced. Foralumab is the only fully human anti-CD3 monoclonal antibody.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TLSA:
- Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
- Tiziana Life Sciences announces purchase of common shares by chairman
- Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
- Tiziana Life Sciences Highlighted in Forbes Article
- Tiziana Life Sciences announces FORBES article highlighting foralumab